Bachmann André S
Cancer Research Center of Hawai'i, Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawai'i at Mãnoa, Honolulu, HI, USA.
Hawaii Med J. 2008 Sep;67(9):247-9.
The 26S proteasome regulates the degradation of many proteins involved in cell cycle control, apoptosis, and tumor growth. The inhibition of the proteasome by specific inhibitors is a viable target for anti-tumor therapy Most prominently, the proteasome inhibitor bortezomib (Velcade) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory multiple myeloma in adults, and is presently considered for several other types of cancer including pediatric malignancies. The first clinical trials by the Children's Oncology Group (COG) were conducted with bortezomib for the treatment of refractory solid tumors and refractory leukemia. Proteasome inhibitors are a promising new class of therapeutics that should be further explored in combination with other chemotherapeutic agents for the treatment of pediatric cancer patients.
26S蛋白酶体调节许多参与细胞周期控制、细胞凋亡和肿瘤生长的蛋白质的降解。用特异性抑制剂抑制蛋白酶体是抗肿瘤治疗的一个可行靶点。最显著的是，蛋白酶体抑制剂硼替佐米（万珂）已被美国食品药品监督管理局（FDA）批准用于治疗成人复发或难治性多发性骨髓瘤，目前正在考虑将其用于包括儿童恶性肿瘤在内的其他几种癌症类型的治疗。儿童肿瘤学组（COG）开展的首批临床试验是使用硼替佐米治疗难治性实体瘤和难治性白血病。蛋白酶体抑制剂是一类有前景的新型治疗药物，应进一步探索其与其他化疗药物联合用于治疗儿童癌症患者。
